Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibition and immunotherapy: a promising duo in fighting cancer

1 Sept 2023

Abstract excerpt

Yap and colleagues' (1) recent work reports the results of a large, phase 1b and 2 basket, nonrandomized trial exploring the combination of avelumab [anti-programmed deathligand 1 (PD-L1)] and talazoparib [oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi)] in solid tumors.Their work builds on an ever-growing preclinical literature to examine patient-level, clinical viability of this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37859734
DOI: 10.21037/tcr-23-726

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibition and immunotherapy: a promising duo in fighting cancerPMID 37859734Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

The potential of PARP inhibitors in targeted cancer therapy and immunotherapySemantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read ↗

The DNA Damaging Revolution: PARP Inhibitors and BeyondSemantic proximity Read ↗

Strategies for the prevention or reversal of PARP inhibitor resistance.Semantic proximity Read ↗

Update on Combination Strategies of PARP InhibitorsSemantic proximity Read ↗

Targeting DNA damage repair precision medicine strategies in cancerSemantic proximity Read ↗

PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancersSemantic proximity Read ↗

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical ImplicationsSemantic proximity Read ↗

[Cancer therapy by PARP inhibitors].Semantic proximity Read ↗

Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune CheckpointsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.